Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation
- PMID: 18049940
- DOI: 10.1080/13697130701624971
Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation
Abstract
Objectives: Equol, a gut bacterial metabolite of the isoflavone daidzein, has been associated with beneficial health effects. Recent studies indicate that women with intestinal capacity to convert daidzein to equol also have the capacity to alter steroid metabolism and bioavailability of estrogens.
Methods: We evaluated whether individual equol production capability, while not consuming soy supplement, was associated with lower blood pressure in postmenopausal women using tibolone. In addition, in a randomized, placebo-controlled, cross-over trial we assessed the effect of soy supplementation on blood pressure in both equol-producing (n = 20) and non-equol-producing (n = 20) women using tibolone. Blood pressure was recorded with a validated oscillometric technique.
Results: The circulating equol levels rose 20-fold in the equol producers and 1.9-fold in the non-equol producers. At baseline, systolic blood pressure (129.9 +/- 2.6 vs. 138.5 +/- 3.1 mmHg, p = 0.02), diastolic blood pressure (72.2 +/- 1.5 vs. 76.6 +/- 1.3 mmHg, p = 0.01) and mean arterial blood pressure (93.5 +/- 1.7 vs. 99.9 +/- 1.8 mmHg, p = 0.007) were lower in equol producers compared to non-equol producers. Soy supplementation had no effect on blood pressure in either group, whereas the baseline differences persisted.
Conclusions: Postmenopausal women using tibolone characterized as equol producers had lower blood pressure compared to non-equol producers. Soy supplementation for 2 months had no blood pressure-lowering effect.
Similar articles
-
Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation.Atherosclerosis. 2008 May;198(1):174-8. doi: 10.1016/j.atherosclerosis.2007.09.010. Epub 2007 Oct 24. Atherosclerosis. 2008. PMID: 17961576 Clinical Trial.
-
Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal women using tibolone: role of equol production capability.Climacteric. 2008 Oct;11(5):409-15. doi: 10.1080/13697130802251344. Climacteric. 2008. PMID: 18781486 Clinical Trial.
-
Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes.Maturitas. 2006 Feb 20;53(3):315-24. doi: 10.1016/j.maturitas.2005.05.016. Epub 2005 Jul 12. Maturitas. 2006. PMID: 16019168
-
Postmenopausal HRT and tibolone in relation to muscle strength and body composition.Maturitas. 2007 Sep 20;58(1):7-18. doi: 10.1016/j.maturitas.2007.04.012. Epub 2007 Jun 18. Maturitas. 2007. PMID: 17576043 Review.
-
Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype?Nutr Rev. 2007 Jun;65(6 Pt 1):294-9. doi: 10.1301/nr.2007.jun.294-299. Nutr Rev. 2007. PMID: 17605306 Review.
Cited by
-
Role of S-Equol, Indoxyl Sulfate, and Trimethylamine N-Oxide on Vascular Function.Am J Hypertens. 2020 Sep 10;33(9):793-803. doi: 10.1093/ajh/hpaa053. Am J Hypertens. 2020. PMID: 32300778 Free PMC article. Review.
-
Research protocol: effect of natural S-equol on blood pressure and vascular function--a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension.BMC Complement Altern Med. 2016 Mar 1;16:89. doi: 10.1186/s12906-016-1065-5. BMC Complement Altern Med. 2016. PMID: 26928904 Free PMC article. Clinical Trial.
-
Does equol production determine soy endocrine effects?Eur J Nutr. 2012 Jun;51(4):389-98. doi: 10.1007/s00394-012-0331-7. Epub 2012 Feb 25. Eur J Nutr. 2012. PMID: 22366740 Review.
-
Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial.Am J Clin Nutr. 2016 Mar;103(3):694-702. doi: 10.3945/ajcn.115.125690. Epub 2016 Feb 3. Am J Clin Nutr. 2016. PMID: 26843154 Free PMC article. Clinical Trial.
-
The Effect of Eqoul, a Metabolite of Isoflavone, on Endothelial Cell-independent Vasodilatation of Human Uterine Artery In Vitro.J Bone Metab. 2015 May;22(2):57-69. doi: 10.11005/jbm.2015.22.2.57. Epub 2015 May 31. J Bone Metab. 2015. PMID: 26082915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources